Navigation Links
PPD Confirms Takeda's NDA Filing of Alogliptin with U.S. Food and Drug Administration
Date:2/28/2008

Triggers $15 million milestone payment

WILMINGTON, N.C., Feb. 28 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today confirmed that Takeda Pharmaceutical Company Limited's new drug application (NDA) for alogliptin, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, has been accepted for filing by the U.S. Food and Drug Administration. PPD partnered with Takeda to develop the compound.

Under PPD's agreement with Takeda, the FDA's acceptance of the NDA filing triggers a $15 million milestone payment to PPD. This milestone payment was included in PPD's previously issued 2008 financial guidance.

"We are pleased to partner with Takeda, one of the leading pharmaceutical companies in the area of diabetes," said Fred Eshelman, PPD's chief executive officer. "We are also delighted that this important regulatory milestone has been achieved as a result of close cooperation between Takeda and our company."

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,200 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the alogliptin NDA filing with the FDA, subsequent milestone payments for regulatory approvals for alogliptin, if any, the continued developmen
'/>"/>

SOURCE PPD, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
2. Icahn Confirms Intention to Nominate Three Directors at Biogen
3. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
4. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
5. Barr Confirms Patent Challenge of Focalin(R) XR
6. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
9. Durameds Lo SEASONIQUE(R) NDA Accepted for Filing by FDA
10. Attagenes Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods
11. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... today announced a collaboration with University of California, ... test ImmunoPulse™ IL-12 as an immunotherapy in dogs ... the canine study are to advance the understanding ... and validate key clinical biomarkers. ...
(Date:6/1/2015)... Calif. , June 1, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... a Phase 2 clinical trial of AST-VAC1 in ... leukemia (AML). AST-VAC1 is the Company,s autologous (using ... cancer vaccine. AML is the most common form ...
(Date:5/31/2015)... BARCELONA, Spain , June 1, 2015 /PRNewswire/ ... company dedicated to rare diseases, has selected Veeva ... across sales, marketing, and medical. A complete solution, ... data, multichannel interactions, and compliant content to provide ... and effective commercial execution.      (Logo: ...
(Date:5/31/2015)... Grow Med University (GMU) is a free, ... at their own pace and dip into the rich ... both scientific and other informative articles, to hone their ... harvest yet! , The medical marijuana industry is ... in the U.S. and a slew of other businesses ...
Breaking Biology Technology:OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 2Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 5Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 6Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 7Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 3Grow Med University: a Brand New Online Hydroponics Course 2
... ATLANTA, Sept. 24 GeoVax Labs, Inc. ... company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), ... in the recently completed Phase 3 trial in Thailand of ... for Infectious Diseases. The completed study represents the first HIV/AIDS ...
... NEW YORK, Sept. 24 Reportlinker.com announces that a ... , Stem Cell Therapeutics Markets ... Political and business events presage change for stem cell ... lift federal funding restrictions on stem-cell research. The U.S. Congress has ...
... , , , ... CALP ), a leading provider of tools and services ... of XenoLight Rediject reagents at the World Molecular Imaging ... in an expanding range of XenoLight reagents for Caliper,s IVIS optical ...
Cached Biology Technology:Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 2Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 3Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 4Reportlinker Adds Stem Cell Therapeutics Markets Report 2Reportlinker Adds Stem Cell Therapeutics Markets Report 3Reportlinker Adds Stem Cell Therapeutics Markets Report 4Reportlinker Adds Stem Cell Therapeutics Markets Report 5Reportlinker Adds Stem Cell Therapeutics Markets Report 6Reportlinker Adds Stem Cell Therapeutics Markets Report 7Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 2Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 3
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Louisiana, US - Alligators display the same loyalty to ... in Molecular Ecology . The ten-year-study by scientists from ... of females chose to remain with their partner, often for ... Ruth Elsey, Tracey Tuberville and Stacey Lance, spent a decade ...
... in Spanish . , Individuals who follow ... grains and fish- appear less likely to develop depression, according ... the October issue of Archives of General Psychiatry . ... to be lower in Mediterranean than Northern European countries, according ...
... , This release is available in German . ... selectively transcribe parts of the DNA that makes up its genome ... proteins synthesized by a cell in turn determines its structure and ... crucial that the appropriate stretches of DNA are transcribed in each ...
Cached Biology News:Loyal alligators display the mating habits of birds 2Mediterranean diet associated with reduced risk of depression 2How RNA polymerase II gets the go-ahead for gene transcription 2How RNA polymerase II gets the go-ahead for gene transcription 3
WTAP Antibody...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: